Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned a $17.00 price objective by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The firm presently has a “hold” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 9.68% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and issued a $26.00 target price (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and issued a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Sanford C. Bernstein cut Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $42.00 to $28.00 in a report on Friday, August 4th. Maxim Group reiterated a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Finally, Credit Suisse Group reiterated an “outperform” rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and an average price target of $32.94.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 23.81% during mid-day trading on Monday, hitting $19.19. 67,342,823 shares of the stock traded hands. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $52.66. The firm’s market capitalization is $19.50 billion. The company has a 50-day moving average of $20.66 and a 200 day moving average of $29.07.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the previous year, the firm earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. On average, equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Teva Pharmaceutical Industries Limited (TEVA) a $17.00 Price Target” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/11/cantor-fitzgerald-analysts-give-teva-pharmaceutical-industries-limited-teva-a-17-00-price-target.html.

A number of institutional investors have recently bought and sold shares of TEVA. Capital Research Global Investors grew its stake in Teva Pharmaceutical Industries Limited by 13.8% during the 2nd quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. Franklin Resources Inc. grew its stake in Teva Pharmaceutical Industries Limited by 11.1% during the 2nd quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC grew its stake in Teva Pharmaceutical Industries Limited by 16.7% during the 2nd quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Capital World Investors grew its stake in Teva Pharmaceutical Industries Limited by 41.9% during the 2nd quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after purchasing an additional 3,268,200 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in Teva Pharmaceutical Industries Limited by 32.3% during the 2nd quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock valued at $378,688,000 after purchasing an additional 2,782,257 shares during the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.